NCT07084246

Brief Summary

The purpose of this study is to evaluate the effectiveness and safety of the investigational drug on blood pressure and LDL cholesterol control during the observation period in patients who have undergone percutaneous coronary intervention (PCI) in actual clinical practice.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,563

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 7, 2023

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

July 16, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 24, 2025

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

July 24, 2025

Status Verified

July 1, 2025

Enrollment Period

2.5 years

First QC Date

July 16, 2025

Last Update Submit

July 16, 2025

Conditions

Hypertension, Dyslipidemia

Outcome Measures

Primary Outcomes (1)

  • The proportion of participants who meet the treatment goals for BP and LDL-C

    From enrollment to the end of treatment at 24 weeks

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

A patient population with a history of undergoing PCI

You may qualify if:

  • \. Adults aged 19 years and older, both male and female. 2. Patients who have undergone percutaneous coronary intervention (PCI) and are receiving antihypertensive and dyslipidemia-related medications.
  • \. Individuals who require the administration of the investigational product based on the investigator's medical judgment in accordance with approved indications.
  • \. Individuals who can understand the information provided to them and are able to voluntarily sign the informed consent form.

You may not qualify if:

  • \. Individuals who fall under the contraindications for administration according to the approved indications of the investigational product.
  • \. Individuals who have a history of receiving the investigational product prior to participation in this study.
  • \. Individuals whom the investigator deems unsuitable for participation in this observational study for any other reason.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

GC Biopharma

Yŏngin, South Korea

Location

MeSH Terms

Conditions

HypertensionDyslipidemias

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 16, 2025

First Posted

July 24, 2025

Study Start

June 7, 2023

Primary Completion

December 1, 2025

Study Completion

December 1, 2025

Last Updated

July 24, 2025

Record last verified: 2025-07

Locations

KR(1)